CN105250261A - Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat - Google Patents
Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat Download PDFInfo
- Publication number
- CN105250261A CN105250261A CN201510799976.4A CN201510799976A CN105250261A CN 105250261 A CN105250261 A CN 105250261A CN 201510799976 A CN201510799976 A CN 201510799976A CN 105250261 A CN105250261 A CN 105250261A
- Authority
- CN
- China
- Prior art keywords
- theaflavin
- radix
- polyunsaturated fatty
- fatty acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of medicinal health, and particularly relates to a pharmaceutical composition which is prepared by combination of polyunsaturated fatty acids and theaflavin and has an effect of lowering blood fat. The polyunsaturated fatty acids and theaflavin used as main effective ingredients are combined with beneficial effects of the polyunsaturated fatty acids and the theaflavin in the aspect of lowering blood fat. Tests prove that the composition can be used for remarkably reducing the blood-fat level and ambulatory arterial stiffness index of an experimental animal and effectively controlling the blood-fat level. The composition is completely prepared from natural animal and plant ingredients which are used as effective ingredients, has the advantages of wide material source, low production cost, no dependence after long-time taking, no toxic or side effect and the like, is safe and effective, and is suitable for large-scale popularization and application.
Description
Technical field
The present invention relates to medical and health field, relate to a kind of be principle active component medicine and the application of this pharmaceutical composition in treatment hyperlipidemia and relevant disease thereof of theaflavin and polyunsaturated fatty acid particularly.
Background technology
Hyperlipemia a kind ofly common disorderly causes cardiovascular disease by the disorderly class of blood lipid metabolism.Often show as serum total cholesterol (TC) or triglyceride (TG) level is too high and (or) HDL-C (HDL-C) is too low.Hyperlipemia is commonly encountered diseases and the frequently-occurring disease of person in middle and old age, along with the change of the lifting of living standard in recent years, living habit and dietary structure, causes hyperlipidemia population constantly to increase, and presents rejuvenation trend.The atherosclerosis that hyperlipemia causes is the main cause of bringing out coronary heart disease, hypertension, cardiovascular and cerebrovascular disease, and closely related with diabetes, and it is high that these diseases all exist sickness rate, endangers large feature.The whole world about has 1,200 ten thousand people to die from cardiovascular and cerebrovascular disease every year.In recent years a large amount of epidemiological studies shows, obvious ascendant trend has all appearred in Europe, Asia, Americas minor cardiovascular disease prevalence, and this constitutes serious threat to pupillary health.Carrying out intervening for dyslipidemia is the basis of cardiovascular diseases's primary prevention and secondary prevention, and therefore, the treatment of hyperlipemia causes the attention of global medical circle, researches and develops novel blood lipid-lowering medicine and has important practical significance.
Western medicine has determined curative effect, the feature such as rapid-action and being used widely clinically in treatment hyperlipemia.The blood fat reducing Western medicine of current clinical normal use mainly contains Statins, shellfish special class, nicotinic acid class, cholic acid chelating agent class etc., wherein statins is the first-line drug of status of all having the advantage in drug effect, safety now, effectively can reduce LDL-C and TG in serum.The effectiveness comparison that the special class of shellfish reduces TG is obvious, and extended-release niacin performance in lifting HDL-C is good, and cholesterol absorption inhibitor, cholic acid chelating agent mainly reduces LDL-C.Although chemical classes fat-reducing medicament determined curative effect, great majority effect is single, have easily cause hepatic injury, organic disease, easily bounce-back relapse rate high, need the shortcomings such as Long-term taking medicine, clinical practice also has larger limitation.
Relative to Western medicine, in recent years, Chinese medicine is applied in treatment hyperlipemia more and more, and the effective ingredient with effect for reducing fat is constantly separated.Along with the continuous progress of modern means of science and technology, numerous Chinese and overseas scholars carries out studying the effect for reducing fat finding Chinese medicine to the composition in Chinese medicine with Lipid-lowering activities and mainly embodies from the absorption of suppression cholesterol, adjusting blood lipid metabolism, promotion Cholesterol Excretion, scientifically explain the therapy mechanism of Chinese medicine, for application treatment by Chinese herbs hyperlipemia provides theoretical foundation.Reducing Blood Lipid by Chinese medicine has Mutiple Targets, overall coordination effect, advantage that untoward reaction is few, is the focus development object of following blood lipid-lowering medicine.Existing part antilipemic Chinese herbal medicine in the market, single major part is using effective ingredient in Chinese, compound extract, single medicinal substances extract as effective ingredient, and this is not easy to the performance of quality control and drug effect, is also not easy to the monitoring of untoward reaction.
Summary of the invention
An object of the present invention is to provide a kind of determined curative effect, safe ready, side effect is little, quality controllability is strong novel blood lipid-lowering medicine, particularly this blood lipid-lowering medicine with theaflavin and polyunsaturated fatty acid for effective ingredient composition.
According to a preferred embodiment of pharmaceutical composition of the present invention, described polyunsaturated fatty acid is one or more in docosahexenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), gamma-Linolenic acid (GLA); Described theaflavin is by theaflavin (theaflavin, TF), TF-3-G (theaflavin-3-gallate, TF-3-G), TF3 (theaflavin-3 '-gallate, TF-3 '-G) and theaflavin-3,3 '-digallic acid ester (theaflavin-3,3 '-gallate, TF-3,3 '-G) etc. one or more in monomer.
According to a preferred embodiment of pharmaceutical composition of the present invention, described polyunsaturated fatty acid and theaflavin can adopt their derivant or salt to replace.
According to a preferred embodiment of pharmaceutical composition of the present invention, the present composition preferably forms with EPA, DHA and theaflavin
According to a preferred embodiment of pharmaceutical composition of the present invention, compositions is made up of the raw material of following weight proportion:
Theaflavin 1-250 part, polyunsaturated fatty acid 1-200 part;
Further, said composition is made up of the raw material of following weight proportion:
Theaflavin 20-200 part, polyunsaturated fatty acid 15-120 part;
Further, said composition is made up of the raw material of following weight proportion:
Theaflavin 50-150 part, polyunsaturated fatty acid 30-80 part.
According to a preferred embodiment of pharmaceutical composition of the present invention, other complementary compositions of same or similar activity wherein can also be had containing one or more.
According to a preferred embodiment of pharmaceutical composition of the present invention, wherein other complementary compositions said are selected from natural plant extracts or partial chemical synthetic.
According to a preferred embodiment of pharmaceutical composition of the present invention, wherein one or more pharmaceutically acceptable carrier or excipient can also be contained.
Another object of the present invention is to provide the pharmaceutical composition that is defined as above and is producing for the application in the medicine of prevention and therapy hyperlipemia and relevant disease thereof.Described relevant disease includes but not limited to the diseases such as atherosclerosis, coronary heart disease, cerebral thrombosis, obesity, hyperglycemia.
The present invention relates to the new pharmaceutical composition be substantially made up of polyunsaturated fatty acid and theaflavin, especially a kind of pharmaceutical composition be made up of EPA, DHA and theaflavin is related to, and the application of said composition in the medicine producing prevention and therapy hyperlipemia and relevant disease thereof.
As everyone knows, the polyunsaturated fatty acid being representative with EPA and DHA has pharmacological action widely, is of value to health.EPA and DHA is the nutrient substance that mammal self can not be synthesized, and is the highly unsaturated fatty acid of needed by human, has very important effect in growth in humans, growth course.EPA at promotion infant intelligent development, promote nervous system development, antiinflammatory, protection cardiovascular system, anticancer etc. in there is positive role.The approach that EPA reduces cardiovascular disease incidence rate is diversified, mainly reduces the incidence rate of cardiovascular disease by improving lipid metabolism.As EPA can reduce the level of serum triglycerides, cholesterol, low density lipoprotein, LDL, increase the deposition that hdl level reduces lipid in blood vessel, strengthen blood vessel inner skin cell function, prevention of arterial is atherosis.EPA can suppress the synthesis of endogenous cholesterol simultaneously, increases the excretion of cholesterol, changes fatty acid composition in lipoprotein, increases blood fluidity, thus angiocardiopathy preventing.
Theaflavin (theaflavins, TFs) be that a class that tea polyphenols substance oxidation is formed can be dissolved in ethyl acetate, the tall and erect phenol ketonic compound of benzene a pair of horses going side by side containing multiple hydroxyl or phenolic hydroxyl group, it is the main component of tea pigment, have 12 kinds of components, wherein theaflavin (TF), TF-3-G (TF-3-G), TFDG (TFDG) and TF-3'-G (TF-3 '-G) are 4 kinds of topmost theaflavin.Forming primarily of simple catechin and nutgall catechin pairing oxidative condensation in Tea Processing, is the main component in black tea.Theaflavin has multiple potential effect relevant with health, has the effect such as antioxidation, cancer-resisting, blood fat reducing, angiocardiopathy preventing, anti-bacteria and anti-virus.Related Experimental Study shows, the cell that theaflavin overloads at fatty acid and animal model all show and reduces lipid accumulation, suppress fatty acid synthesis and stimulate the effect of fatty acid oxidation, in addition, also by stimulating AMPK/LKB1 path to suppress acetylcoenzyme-A-decarboxylase, demonstrate anti-fatty liver activity.In addition theaflavin can also reduce the absorption of intestinal cholesterol, and then reduces cholesterolemia content.Theaflavin also has stronger Cardiovascular, such as theaflavin passes through the PI3k/Akt path of p38MAPK path and Mediated by Estrogen Receptor, improves eNOS activity and promotes eNOS generation, promoting the generation of vascular relaxing factor NO, diastole coronary artery rings, reduces cardiovascular event risk.
The present invention's combination is containing EPA or DHA, the theaflavin as active component, and one or more pharmaceutically acceptable carrier and/or diluent.If desired, the present composition can also have other Supplementary active ingredients of the natural of same or similar effect or chemosynthesis containing one or more.Other Supplementary active ingredients of natural origin include but not limited to Radix Ginseng, Radix Puerariae, Semen Cassiae, Herb Gynostemmae Pentaphylli, Radix Polygoni Multiflori, the Cortex Eucommiae, Rhizoma Curcumae Longae, Rhizoma Polygoni Cuspidati, the Rhizoma Pinelliae, Radix Bupleuri, Lentinus Edodes, Fructus Lycii, propolis, Ganoderma, Folium Acanthopanacis Senticosi, Thallus Porphyrae, Rhizoma Coptidis, Fructus Ligustri Lucidi, Cordyceps, Bulbus Allii, Radix Achyranthis Bidentatae, pollen, Herba Taxilli, Fructus Cannabis, Radix Angelicae Sinensis, Herba Portulacae, Cera Flava, Pollen Typhae, Semen sojae atricolor, Radix Salviae Miltiorrhizae, fire Folium Kaki, Ramulus Euonymi, Radix Notoginseng, Myrrha, Pinus densiflora leaf, Sanguis Draxonis, Flos Carthami, Folium Nelumbinis, Folium Ginkgo, Rhizoma Alismatis, Thallus Laminariae (Thallus Eckloniae), Radix Oenotherae erythrosepalae, Flos Chrysanthemi, Fructus Hippophae, Yan Bai, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Radix Rhapontici, Radix Glycyrrhizae, Testa oryzae etc. or their effective site and extract.Other Supplementary active ingredients of chemosynthesis include but not limited to lovastatin, bezafibrate, clofibrate, Ji Feibeite, vitamin B, vitamin C etc.The present composition effectively can reduce triglyceride in high fat animal serum, low density lipoprotein, LDL (LDL) through test confirmation, improve high density lipoprotein (HDL), not only can be used for the hyperlipidemia that prevention and therapy comprises hypercholesterolemia, high triglyceride blood disorder, but also can be used for the prevention and therapy other diseases relevant to dyslipidemia.These diseases include but not limited to atherosclerosis, obesity, hypertension, coronary heart disease, cerebral thrombosis, fatty liver and diabetes etc.
The present composition can be prepared into tablet, capsule, pill, powder, suppository, solution, suspensoid etc. according to method known in pharmaceuticals industry.Wherein preferably be applicable to the capsule through gastrointestinal administration and tablet, optimum is lipomul and soft capsule.When preparing the preparation of corresponding oral administration administration, sucrose, lactose, galactose, corn starch, gelatin, microcrystalline Cellulose, micropowder silica gel, carboxymethyl cellulose etc. can be used as carrier or excipient.
In addition, also any means known and complementary composition in pharmaceuticals industry can be adopted the present composition to be prepared into the solution or suspensoid being suitable for parenteral route, can use distilled water, water for injection, isotonic sodium chlorrde solution or glucose solution, or low concentration phosphate buffered solution is as carrier or diluent.Can add one or more other auxiliary elements or additives in these parenteral formulation, such as, ascorbic acid can be used as antioxidant, use sodium benzoate etc. are as antiseptic.In these formulations, other suitable solubilizing agents, disintegrating agent, lubricant, coloring agent, dispersant or surfactant can also be contained.
Present invention incorporates polyunsaturated fatty acid and theaflavin in blood fat reducing a little, prepared medicine achieves comparatively much progress relative to prior art.The present composition has synergism in drug effect, and action target spot is complementary, acts on more comprehensive.Polyunsaturated fatty acid mainly by be combined with cholesterol generate fusing point low, be easy to operate, the ester of metabolism and excretion, change cholesterol distribution in vivo, reduce fat ester deposition in blood vessel wall and play the effect of blood fat reducing; Theaflavin is by reducing gastrointestinal tract digesting and assimilating for lipid, promotes that the oxidative metabolism of body lipid plays effect for reducing blood fat.Polyunsaturated fatty acid is the material be very easily oxidized, and theaflavin has significant vivo and vitro antioxidant activity, and the two coupling can make medicine more stable, reduces the oxidation of drug that in production and application process, exopathogenic factor causes and loses efficacy.In addition, polyunsaturated fatty acid long-term taking easily organizes the greasy taste of resistance, affect spleen and stomach function, the vasodilative effect of theaflavin can significantly improve gastrointestinal microcirculation function, also can improve the vasotonia situation because lipidosis occurs simultaneously, the two coupling can not only eliminate the side effect of polyunsaturated fatty acid, can also promote absorbing and improvement to hyperlipemia syndrome of medicine.The present invention uses natural drug monomeric substance as active ingredient, has Western medicine determined curative effect, clear and definite, the efficient feature of target spot concurrently, also has the advantages such as natural drug side effect is low, cost is low, Mutiple Targets synergy, giving consideration to both the incidental and fundamental simultaneously.The present composition has efficiently, regulate and control the effect of blood fat comprehensively, and side effect is minimum, system easy to control the quality, as a kind of new blood lipid-lowering medicine, can be widely used in the prevention and therapy of clinical hyperlipidemia and relevant disease thereof.
Following examples are intended to further illustrate the present composition, instead of restriction the present invention.Under the prerequisite without prejudice to the present invention's spirit and principle, any change carry out the indivedual technical step of invention or change all will fall in scope.
Detailed description of the invention
Embodiment 1
Take EPA6g, theaflavin (TF) 9.75g and commercially available microcrystalline Cellulose 10g respectively, after mixing, cross 60 mesh sieves.In the mixture of gained, spray into the ethanol 6ml of 95%, again cross 30 mesh sieves after stirring and evenly mixing and obtain granule, load No. 1 capsule in 55 DEG C of dryings after 1.5 hours, make hard capsule.
Embodiment 2
Take DHA7.5g, theaflavin (TF) 8.5g, theaflavin (TF-3-G) 2.5g respectively, add corn starch 15g, microcrystalline Cellulose 10g, 30 POVIDONE K 30 BP/USP
3080 mesh sieves are crossed after 3g, carboxymethyl starch sodium 7g mixing.In gained mixture, add 95% ethanol 10ml, be uniformly mixed rear mistake 30 mesh sieve and be prepared into wet granular, then in 45 DEG C of baking oven inner dryings 1.5 hours, stir granule once every 30 minutes.After dried granule crosses 20 mesh sieve granulate, add appropriate magnesium stearate mix homogeneously, compacting standby one-tenth tablet.
Embodiment 3
Take DHA7.5g, theaflavin (TF-3-G) 3.5g, theaflavin (TFDG) 4.5g respectively, add corn starch 10g, microcrystalline Cellulose 15g, 30 POVIDONE K 30 BP/USP
3080 mesh sieves are crossed after 3g, carboxymethyl starch sodium 7g mixing.In gained mixture, add 95% ethanol 10ml, be uniformly mixed rear mistake 30 mesh sieve and be prepared into wet granular, then in 45 DEG C of baking oven inner dryings 1.5 hours, stir granule once every 30 minutes.After dried granule crosses 20 mesh sieve granulate, add appropriate magnesium stearate mix homogeneously, compacting standby one-tenth tablet.
Embodiment 4
Take EPA4g, theaflavin (TFDG) 16g respectively, add appropriate pharmaceutic adjuvant, technique is prepared into oral liquid routinely.
Embodiment 5
Take EPA15g, DHA8g, theaflavin 5g respectively, add after the right amount of auxiliary materials such as glycerol triacetate, Macrogol 600, tween 80, vitamin C dissolve mixing and be pressed into soft capsule on encapsulating machine.
Embodiment 6
Take EPA20g, theaflavin 5g respectively, add appropriate pharmaceutic adjuvant, technique is prepared into Emulsion routinely.
Pharmacodynamic experiment
Test example 1 present composition lipid-lowering test
1. test method
After healthy mice adaptability is fed 1 week, random packet, be respectively blank group, hyperlipidemia model group, positive controls, EPA group, DHA group, theaflavin group and tested group (test medicine is prepared by embodiment 1,2), often organize 8, weigh and keep a record, weight differences not statistically significant between each group.Experiment mice is except blank group, and all the other respectively organize feeding high lipid food to induce the formation of hyperlipidemia.After 4 weeks, 4 mices are respectively extracted at random from blank group and high fat group, pluck eyeball and get hematometry T-CHOL (TC), triglyceride (TG) and HDL-C (HDL-C) level, to determine the foundation of hyperlipidemia model.
The common Mus grain of blank group feeding, the mice of built vertical hyperlipidemia continues feeding high lipid food, and animal freely ingests and drinks water.Each test group of animals is by given drug dose gastric infusion, and blank is organized and hyperlipidemia model group gavage equivalent distilled water.Continuous gavage is fasting 24h after 3 weeks, plucks eyeball and get blood and liver after weighing, and measures the concentration of TC, TG and HDL-C indices.All experimental datas all adopt SPSS11.5 statistical processing software to carry out statistical procedures, and group difference adopts t inspection, and P<0.05 is that difference has statistical significance.
2. experimental result
The lipid-lowering effect of 2.1 present compositions
High lipid food fed mice after 4 weeks, and sampling measures the change of lipid of mice level, and concrete outcome is in table 1.
Mice feeds mice after 4 weeks through high lipid food as can be seen from Table 1, mice serum TC, TG content significantly raises (P<0.01), HDL-C content significantly reduces (P<0.01), shows that hyperlipemia in mice model is successfully established.
Table 1 hyperlipidemia animal model contrasts
Note: compare with blank group,
*p < 0.01.
After the compositions that mice prepares to respectively positive drug lovastatin and embodiment 1,2, measure the content of TC, TG and HLD-C in its serum.Result is as shown in table 2, high lipid food group compares with blank group, pathological model group mice serum TC and TG content are all apparently higher than blank group (P<0.01), HLD-C content is all starkly lower than blank group (P<0.01), illustrates that the hyperlipidemia animal model in this experiment is successful.Compared with high fat pathological model group, give embodiment 1,2 compositions and positive controls all significantly reduces mice serum TC and TG content, increase HLD-C content.In addition apply separately DHA, EPA, theaflavin also has obvious effect for reduction mice serum TC, TG content rising HDL-C content, but its effect is not as unsaturated fatty acid and theaflavin use in conjunction.The lipid-lowering effect of embodiment 1,2 is obviously better than its component and applies separately, and the coupling between display present composition effective ingredient achieves the effect of Synergistic.
The lipid-lowering effect of table 2 the present invention combination
Note: compare with blank group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01.
2.2 present compositions are on the impact of atherogenic index
Atherogenic index (AI) can reflect the distribution situation of lipoprotein cholesterol in animal or human's body, and when AI value increases, atherosclerosis risk just increases.Atherogenic index computing formula is: AI=(TC-HDL-C)/HDL-C.Modern study proves, high TC and LDL-C, and low HDL-C is atherosclerotic important risk factor.Therefore, medically conventional atherogenic index AI represents atherosclerotic danger, and AI value raises prompting body and the increase of atherosclerotic probability occurs.As can be seen from Table 3, the AI value of each test group is starkly lower than high fat contrast class value, all reaches significant level (P<0.05).Show that compositions provided by the present invention has good preventive effect to atherosclerosis.
Table 3 present composition is on the impact of atherogenic index
Note: compare with blank group,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01.
Above experimental result shows, compositions provided by the invention effectively can reduce T-CHOL and the triglyceride levels of high blood lipid model mice, high density lipoprotein increasing cholesterol levels, and can atherogenic index be reduced, show that the present composition has good effect for reducing blood fat, and to the relevant disease having hyperlipidemia to bring out, there is certain preventive effect.And compared with existing medicine, said composition is to have the natural product of multiple health care for raw material, safer, has no adverse reaction.
Claims (9)
1. containing theaflavin, there is the crude drug compositions of blood fat reducing function, it is characterized in that it is with polyunsaturated fatty acid and theaflavin for principle active component, routinely the medicament that is prepared from of preparation technique.
2. pharmaceutical composition as claimed in claim 1, is characterized in that it is made up of the raw material of following weight proportion:
Theaflavin 1-250 part, polyunsaturated fatty acid 1-200 part;
Further, said composition is made up of the raw material of following weight proportion:
Theaflavin 20-200 part, polyunsaturated fatty acid 15-120 part;
Further, said composition is made up of the raw material of following weight proportion:
Theaflavin 50-150 part, polyunsaturated fatty acid 30-80 part.
3. polyunsaturated fatty acid as claimed in claim 1, is characterized in that it can be one or more in the purification monomers such as docosahexenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), gamma-Linolenic acid (GLA); Also can be rich in the vegeto-animal extract of unsaturated fatty acid, as one or more in the middle of algae oil, fish oil, Semen Lini oil, Semen arachidis hypogaeae wet goods.
4. theaflavin as claimed in claim 1, it is characterized in that it is by theaflavin (theaflavin, TF), TF-3-G (theaflavin-3-gallate, TF-3-G), TF3 (theaflavin-3 '-gallate, TF-3 '-G) and TFDG (theaflavin-3,3 '-gallate, TF-3,3 '-G) etc. one or more compositions in monomer.
5. the polyunsaturated fatty acid as described in claim 1-4 and theaflavin can also use its pharmaceutically acceptable derivates or salt to replace.
6. the compositions as described in claim 1-4, can also comprise the complementary composition that one or more have the natural of same or similar effect or chemosynthesis.
7. complementary composition as claimed in claim 6, include but not limited to Radix Ginseng, Radix Puerariae, Semen Cassiae, Herb Gynostemmae Pentaphylli, Radix Polygoni Multiflori, the Cortex Eucommiae, Rhizoma Curcumae Longae, Rhizoma Polygoni Cuspidati, the Rhizoma Pinelliae, Radix Bupleuri, Lentinus Edodes, Fructus Lycii, propolis, Ganoderma, Folium Acanthopanacis Senticosi, Thallus Porphyrae, Rhizoma Coptidis, Fructus Ligustri Lucidi, Cordyceps, Bulbus Allii, Radix Achyranthis Bidentatae, pollen, Herba Taxilli, Fructus Cannabis, Radix Angelicae Sinensis, Herba Portulacae, Cera Flava, Pollen Typhae, Semen sojae atricolor, Radix Salviae Miltiorrhizae, fire Folium Kaki, Ramulus Euonymi, Radix Notoginseng, Myrrha, Pinus densiflora leaf, Sanguis Draxonis, Flos Carthami, Folium Nelumbinis, Folium Ginkgo, Rhizoma Alismatis, Thallus Laminariae (Thallus Eckloniae), Radix Oenotherae erythrosepalae, Flos Chrysanthemi, Fructus Hippophae, Yan Bai, Radix Et Rhizoma Rhei, Pericarpium Citri Reticulatae, Radix Rhapontici, Radix Glycyrrhizae, Testa oryzae etc. or their effective site and extract, or the chemosynthesis material such as lovastatin, bezafibrate, clofibrate, Ji Feibeite, vitamin B, vitamin C.
8. the pharmaceutical composition as described in claim 1-7, conveniently can be prepared into the medicine of different dosage form by preparation technique, and be preferably peroral administration pharmaceutical dosage form, more excellent is Orally taken emulsion or soft capsule.
9. the pharmaceutical composition as described in claim 1-8 is producing the application in the medicine being used for prevention and therapy hyperlipemia and relevant disease thereof, and described relevant disease includes but not limited to the diseases such as atherosclerosis, coronary heart disease, cerebral thrombosis, obesity, hyperglycemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510799976.4A CN105250261A (en) | 2015-11-19 | 2015-11-19 | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510799976.4A CN105250261A (en) | 2015-11-19 | 2015-11-19 | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250261A true CN105250261A (en) | 2016-01-20 |
Family
ID=55090400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510799976.4A Pending CN105250261A (en) | 2015-11-19 | 2015-11-19 | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250261A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796493A (en) * | 2016-03-31 | 2016-07-27 | 中国农业科学院茶叶研究所 | Preparation method of theaflavin micro emulsion |
| WO2017180127A1 (en) * | 2016-04-14 | 2017-10-19 | Lucey Michael | Combinational compositions and methods of use thereof |
| CN108066723A (en) * | 2016-11-16 | 2018-05-25 | 成都普睿法药物研发有限公司 | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
| CN110840881A (en) * | 2019-10-17 | 2020-02-28 | 广东省农业科学院茶叶研究所 | Application of theaflavin TF3 in preparation of PK inhibitor and medicine for treating NAFLD |
| CN112807374A (en) * | 2020-12-27 | 2021-05-18 | 满山歌茶业(西双版纳)有限公司 | Compound preparation for preventing and treating diabetes and complications thereof and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452961A (en) * | 2002-04-26 | 2003-11-05 | 上海科宝生物技术有限公司 | New use of theaflavin |
| CN103908523A (en) * | 2014-04-29 | 2014-07-09 | 重庆海立云科技有限公司 | Method for extracting tea pigment from tea leaves and tea pigment soft capsule |
-
2015
- 2015-11-19 CN CN201510799976.4A patent/CN105250261A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452961A (en) * | 2002-04-26 | 2003-11-05 | 上海科宝生物技术有限公司 | New use of theaflavin |
| CN103908523A (en) * | 2014-04-29 | 2014-07-09 | 重庆海立云科技有限公司 | Method for extracting tea pigment from tea leaves and tea pigment soft capsule |
Non-Patent Citations (3)
| Title |
|---|
| 于跃芹等编著: "《有机化学》", 30 June 2010, 科学出版社 * |
| 张艳等: "《养心论》", 31 January 2011, 辽宁科学技术出版社 * |
| 谭蓉等: "茶黄素软胶囊的制备及其功效评价", 《慢性病学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796493A (en) * | 2016-03-31 | 2016-07-27 | 中国农业科学院茶叶研究所 | Preparation method of theaflavin micro emulsion |
| WO2017180127A1 (en) * | 2016-04-14 | 2017-10-19 | Lucey Michael | Combinational compositions and methods of use thereof |
| CN108066723A (en) * | 2016-11-16 | 2018-05-25 | 成都普睿法药物研发有限公司 | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
| CN110840881A (en) * | 2019-10-17 | 2020-02-28 | 广东省农业科学院茶叶研究所 | Application of theaflavin TF3 in preparation of PK inhibitor and medicine for treating NAFLD |
| CN112807374A (en) * | 2020-12-27 | 2021-05-18 | 满山歌茶业(西双版纳)有限公司 | Compound preparation for preventing and treating diabetes and complications thereof and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250261A (en) | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat | |
| CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
| CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
| JP2020518596A (en) | Chinese herbal medicine extract effective for depression, its preparation method and use | |
| CN103479691B (en) | Fat-reducing liver-protecting Chinese medicine composition | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN102697982A (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| CN109662967A (en) | A kind of antidepressant and application thereof | |
| CN102743458B (en) | Formula of health drug with effects blood fat regulating and immunity increasing | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| CN107213197A (en) | A kind of Chinese medicine composition and its application in prevention or treatment hypertension drug is prepared | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN102772466A (en) | Application of chrysanthemum extract | |
| CN103505507A (en) | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition | |
| CN102793798A (en) | Medicinal composition for auxiliary treatment of diabetic coronary artery disease | |
| Abass | Therapeutic effect of Artemisia herba-alba aqueous extract added to classical therapy of acquired hyperlipidemia | |
| CN108066723A (en) | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160120 |
|
| WD01 | Invention patent application deemed withdrawn after publication |